NCT03561220: COMPPARE

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

Active, enrolled NA Last updated 9 March 2026

What this trial tests

NA trial testing Standard of Care IMRT (Photon) in Prostate Cancer in 3,000 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

5 July 2018

Primary endpoint
15 February 2026

1 July 2027

Quick facts

Lead sponsor	University of Florida
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	3,000
Start date	5 July 2018
Primary completion	15 February 2026
Estimated completion	1 July 2027
Sites	53 locations across United States

Drugs / interventions tested

• Standard of Care IMRT (Photon)
• Standard of Care Proton Therapy
• Proton Arm 1: Standard Proton Therapy
• Proton Arm 2: Hypofractionated Proton Therapy

Conditions studied

• Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University of Florida

Who can join

Adults 30 to 85, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a large, prospective, pragmatic, controlled comparison of patient-centric outcomes \[quality of life (QOL), toxicity, and disease control\] between parallel cohorts of men with prostate cancer treated simultaneously at proton therapy facilities and at geographically similar conventional (photon-based) radiation facilities using intensity-modulated radiation therapy (IMRT) techniques.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Deintensification of Adjuvant Treatment After Transoral Surgery in Patients With Human Papillomavirus-Positive Oropharyngeal Cancer: The Conception of the PATHOS Study and Its Development.
   Hargreaves S, Beasley M, Hurt C, Jones TM, et al · · 2019 · cited 37× · PMID 31632901 · DOI 10.3389/fonc.2019.00936
2. Proton versus photon radiation therapy: A clinical review.
   Chen Z, Dominello MM, Joiner MC, Burmeister JW. · · 2023 · cited 32× · PMID 37064131 · DOI 10.3389/fonc.2023.1133909
3. Consensus Statement on Proton Therapy for Prostate Cancer.
   Bryant CM, Henderson RH, Nichols RC, Mendenhall WM, et al · · 2021 · cited 23× · PMID 34722807 · DOI 10.14338/ijpt-20-00031.1
4. A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients.
   Vapiwala N, Wong JK, Handorf E, Paly J, et al · · 2021 · cited 22× · PMID 33539968 · DOI 10.1016/j.ijrobp.2021.01.043
5. Proton therapy for prostate cancer: current state and future perspectives.
   Wu YY, Fan KH. · · 2022 · cited 18× · PMID 34558308 · DOI 10.1259/bjr.20210670
6. Overall Survival After Treatment of Localized Prostate Cancer With Proton Beam Therapy, External-Beam Photon Therapy, or Brachytherapy.
   Liu Y, Patel SA, Jani AB, Gillespie TW, et al · · 2021 · cited 17× · PMID 32972877 · DOI 10.1016/j.clgc.2020.08.009
7. IMPT versus VMAT for Pelvic Nodal Irradiation in Prostate Cancer: A Dosimetric Comparison.
   Whitaker TJ, Routman DM, Schultz H, Harmsen WS, et al · · 2019 · cited 16× · PMID 31788504 · DOI 10.14338/ijpt-18-00048.1
8. Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine.
   Kamran SC, Efstathiou JA. · · 2021 · cited 10× · PMID 34026653 · DOI 10.3389/fonc.2021.675311